Data from a limited number of patients have shown that ICIs are feasible as monotherapy or combination among HER2-mutant lung cancer, with an ORR of 16%-52% and a median progression-free survival (PFS) of 4-6 months (13). This evidence concerns the gene ERBB2 and lung cancer.